Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors
Clinical trial NCT03911557 · COMPLETED
Trial details
- NCT number
- NCT03911557
- Sponsor
- John L. Villano, MD, PhD
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-08
- Primary completion
- 2025-10-10
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.